Latest News

Readers hoping to buy Arrow Financial Corporation ( NASDAQ:AROW ) for its dividend will need to make their move...

If you are wondering whether Palantir Technologies' current share price fairly reflects its story, this article will walk through what that number might mean for you. Palantir's stock is at US$135.90 after a 7.3% decline over the past week and a 23.4% decline over the past month, even though the 1 year return stands at 22.6% and the 3 year return is very large. Recent coverage around Palantir has focused on its role as a software provider in data analytics and security for government and...

ROHM (TSE:6963) has introduced its BD9xxN5 Series LDO regulator ICs featuring proprietary Nano Cap technology. The new regulators are designed to support higher output currents for automotive, industrial, and communication infrastructure uses. The launch highlights ROHM's push into higher power application areas within key end markets. For investors tracking ROHM at a share price of ¥2,509.5, this product launch comes after a mixed return profile, with a 10.2% gain year to date and a 67.0%...

Atlassian (TEAM) has just posted Q2 2026 results with revenue of US$1.6b and a basic EPS loss of US$0.16, alongside trailing twelve month revenue of US$5.8b and a basic EPS loss of US$0.72 that keeps the company in the red on a full year view. The company has seen quarterly revenue move from US$1.3b in Q2 2025 to US$1.6b in Q2 2026, while quarterly basic EPS over the same periods shifted from a loss of US$0.15 to a loss of US$0.16. This sets up this release as another checkpoint on how...

If you are wondering whether Diebold Nixdorf at US$71.81 is priced attractively or asking too much for its prospects, this overview offers a clear look at what the current share price might imply. The stock has posted returns of 4.1% over the past week, 6.5% over the last 30 days and 12.3% year to date, with a 61.2% return over the past year that may have changed how some investors view its risk and reward profile. Recent company news has focused on Diebold Nixdorf's role in providing...

Intellia Therapeutics (NTLA) is back in focus after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran in hereditary transthyretin amyloidosis with polyneuropathy, allowing enrollment to resume. See our latest analysis for Intellia Therapeutics. The FDA decision lands after a volatile stretch, with a 30 day share price return of 18.30% and a 90 day share price return of 26.21%. However, a 3 year total shareholder return of a 69.28% decline shows how...

Hoist Finance (OM:HOFI) has just wrapped up FY 2025 with fourth quarter total revenue of 1,031 million SEK and basic EPS of 3.84 SEK, while the trailing twelve months show basic EPS of 11.59 SEK supported by net income of 1,014 million SEK and a net margin of 25.9%. The company has seen total revenue move from 1,145 million SEK in Q4 2024 to 1,031 million SEK in Q4 2025, with basic EPS over that period shifting from 2.12 SEK to 3.84 SEK as trailing twelve month earnings growth of 15.4%...

Logitech International (SWX:LOGN) has been in focus after reporting third quarter results and issuing guidance that points to higher expected sales for both the upcoming quarter and the full 2026 fiscal year. See our latest analysis for Logitech International. The recent third quarter results and higher sales guidance sit against a mixed share price backdrop, with a 1-week share price return of 5.58% but a 90-day share price return decline of 25.89%. At the same time, the 3-year total...

Saputo (TSX:SAP) reported margin expansion and profit growth driven by operational efficiencies across its global operations. The company is pursuing facility upgrades and network optimization projects that focus on high protein and value added dairy products. As part of this plan, Saputo is permanently closing its Green Bay, Wisconsin manufacturing facility and consolidating production into other sites. Saputo is a global dairy processor with a presence across cheese, fluid milk, and other...

JD.com (NasdaqGS:JD) is reportedly weighing its first offshore yuan dim sum bond, a potential funding move that sits alongside recent efforts in global logistics, international partnerships, and JD MALL expansion within China. See our latest analysis for JD.com. At a share price of $28.07, JD.com has a 1-day share price return of 2.75%. Its 1-year total shareholder return of 28.10% and 5-year total shareholder return of 68.92% point to fading longer term momentum as investors weigh funding...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Why the Best Western AI partnership matters for Tripadvisor (TRIP) The new AI-powered “Go for the Goal” trip planning platform with Best Western Hotels & Resorts puts Tripadvisor (TRIP) at the center of a specific, time-bound travel use case: multi-city soccer trips for 2026. For you as an investor, this matters because it links three themes that are already in focus around the stock: Tripadvisor’s push into AI, the growing role of its experiences marketplace, and the company’s broader shift...

Infinity Natural Resources, Inc. ( NYSE:INR ) shares have continued their recent momentum with a 26% gain in the last...

What drove the latest reaction to Ladder Capital’s earnings Ladder Capital (LADR) is back in focus after its Q4 2025 earnings missed Wall Street expectations on both revenue and profit, with management pointing to softer net interest income and loan timing effects. See our latest analysis for Ladder Capital. The Q4 2025 miss has fed into recent share price weakness, with a 7 day share price return of 6.38% and a year to date share price return of 7.48%. The 5 year total shareholder return of...

Why HASI's C-Corp shift is back in focus HA Sustainable Infrastructure Capital (HASI) is back on investor radars after recent analysis emphasized its transition to a C-Corporation, highlighting capital retention and a more capital light approach to funding future infrastructure deals. See our latest analysis for HA Sustainable Infrastructure Capital. HASI’s recent C-Corp shift and focus on more capital light deal funding appear to be landing with investors, with a 1-month share price return...

Fuso ChemicalLtd (TSE:4368) has reported solid Q3 2026 numbers, with revenue of ¥20.2b, basic EPS of ¥108.04 and trailing 12 month EPS of ¥372.69, alongside trailing earnings growth of 15.2% and a net profit margin of 17.5%. Over recent quarters the company has seen revenue move from ¥17.1b in Q4 2025 to ¥19.0b in Q2 2026 and ¥20.2b in Q3 2026. Quarterly basic EPS has ranged from ¥69.55 in Q4 2025 to ¥107.02 in Q2 2026 and ¥108.04 in Q3 2026, setting up an earnings story that leans on both...

BILL Holdings (BILL) is back in focus after a sharp stock move tied to a stronger than expected earnings update, higher full year guidance, and fresh M&A chatter involving private equity firm Hellman & Friedman. See our latest analysis for BILL Holdings. The 37.2% 1 day share price return, taking BILL Holdings to US$48.94, came after earnings, raised guidance, and the potential sale discussions shifted how investors view its growth prospects and risks. Even so, the share price return over the...

VeriSign reports 28 consecutive years of 100% domain resolution uptime. The company records its highest level of new domain registrations to date. VeriSign introduces new services focused on online security and stability. VeriSign, trading under NasdaqGS:VRSN, is drawing attention as it pairs a long running record of 100% domain resolution uptime with record high new domain registrations. The stock last closed at $224.17, with a 1 year return of 2.1% and a 5 year return of 11.7%. This...

Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders won't be pleased to see that the share price has had a very rough...

Embrace Home Loans recently announced an agreement with Amalgamated Bank under which Embrace will originate and service residential mortgages for the bank’s customers on a tailored platform. The arrangement allows Amalgamated Bank to broaden its mortgage offering without building its own full-scale origination infrastructure, while still keeping customer relationships at the center of the process. Next, we’ll examine how outsourcing mortgage origination to Embrace Home Loans could influence...

Scandic Hotels Group (OM:SHOT) is back in the news after announcing plans for a new 152 room Scandic Go hotel in central Stavanger, Norway, with opening currently targeted for 2028. See our latest analysis for Scandic Hotels Group. The planned Scandic Go opening in Stavanger comes as the SEK90.5 share price has seen a 1 day share price return of 0.56% and a 7 day share price return of 1.80%, while the 30 day share price return of a 6.41% decline contrasts with a 1 year total shareholder...

If you are wondering whether CAE shares still offer value or if the price already reflects the story, you are in the right place. Over the past week the stock recorded a 2.2% decline, while the 30 day return is a 7.2% decline, set against a modest 0.5% gain year to date and a 25.4% return over 1 year. Across this period, CAE has stayed in focus for investors watching how its training and simulation solutions are being used across civil aviation and defense markets. That context, together...

Why RenaissanceRe’s latest earnings are drawing investor attention RenaissanceRe Holdings (RNR) has come into focus after reporting fourth quarter and full year 2025 results, alongside sizable share repurchases, that sharply contrast with the prior year, particularly on net income and earnings per share. See our latest analysis for RenaissanceRe Holdings. RenaissanceRe’s latest earnings and extensive buybacks appear to sit behind a 10.03% 1 month share price return and a 10.40% year to date...

Health Canada previously granted market authorization for Yorvipath (palopegteriparatide injection), Ascendis Pharma’s parathyroid hormone replacement therapy for adults with chronic hypoparathyroidism, with Pendopharm handling distribution in Canada. This approval adds another international market for Yorvipath and underscores ongoing efforts to secure public and private reimbursement to support patient access. Next, we’ll examine how this Canadian authorization for Yorvipath shapes...